Avacta Group “promising evaluation of the Affimer reagents in Integumen’s sensor systems”

Coronaviruses are a large family of viruses that cause illnesses like the common cold, but can also cause more severe diseases such as Middle East Respiratory Syndrome (MERS) and Sever Acute Respiratory Syndrome (SARS). The novel

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell Therapeutics, the joint venture established in South Korea by the

Testing Therapies, Antivirals and Vaccines Avacta Group has partnered with the U.K. government’s CONDOR program to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry laboratory assay developed with Adeptrix. Adeptrix’s novel BAMS platform uses

Sewage monitoring is being trialled as a way to spot new outbreaks of coronavirus, and three UK companies have now joined forces to try to develop a probe for this purpose. Integumen, Avacta and Modern Water

All health and care staff should be routinely tested for Covid-19 once or twice a week, according to one of the UK’s most eminent scientists, Sir Paul Nurse, whose team’s research suggests 45% of staff were

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announces that it has begun work with the UK government’s CONDOR programme to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry (“BAMSTM“)

Testing Therapies, Antivirals and Vaccines Avacta Group entered into a collaboration with Integumen plc to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in wastewater, to provide a real-time alert

Life sciences business Avacta Group has become the second Yorkshire firm to partner with Integumen on Covid-19 detection systems for wastewater. The Wetherby-based listed firm has entered into a collaboration agreement with Integumen to evaluate its

Avacta Group has won Technology Company of the Year at the Small Cap 2020 Awards. Over 200 attendees, all supporters of the small cap community congregated online at the (optional) black tie event. Companies and advisors

When a disease outbreak occurs, the first stage of the response is detection. In both the Zika and COVID-19 outbreaks, WHO identified effective diagnostics as vital tools in disease management in order to accurately identify the viruses, monitor

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that the first Affimer-based rapid test strips to detect SARS-COV-2 spike protein have been developed and evaluated by Avacta’s partners at Cytiva (formerly GE

In 2003, the outbreak of severe acute respiratory syndrome (SARS) became the first pandemic of the 21st century and exemplified the rapid rate at which a virus can spread internationally. Originating in China, SARS quickly spread

Avacta Group plc, which is the developer of Affimer biotherapeutics and reagents, announced that collaborative work with the Centre for Virus Research at the University of Glasgow has shown that Affimer reagents which bind to the